Levothyroxine Sodium Tablets Recalled for Subpotent Drug Nationwide
Accord Healthcare recalls Levothyroxine Sodium Tablets nationwide due to subpotent drug content. Affected lot #D2400679 may contain below-specification levels of active ingredient.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. Subpotent levothyroxine is a risk-of-harm product where inadequate active ingredient could affect medication efficacy, meeting High severity criteria.
Plain-English summary
Accord Healthcare, Inc. is recalling Levothyroxine Sodium Tablets, USP, 25 mcg in 1000-count bottles distributed nationwide. The affected lot is #D2400679 with expiration date 02/28/2026, and approximately 2,352 bottles have been distributed.
The recall is due to subpotency—testing found the drug assay to be below the approved specification. This means the tablets contain less active ingredient per dose than required.
Consumers with tablets from this lot should contact their pharmacy or healthcare provider to verify whether they received affected bottles and to discuss any necessary follow-up regarding their medication therapy.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- ACCORD HEALTHCARE, INC.
- Category
- Drug — Prescription Medication
- Hazard
- subpotent-drug
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #D2400679
- Exp Date: 02/28/2026
UPCs (12)
- 0316729447157
- 0316729449151
- 0316729452151
- 0316729454155
- 0316729453158
- 0316729448154
- 0316729451154
- 0316729457156
- 0316729450157
- 0316729456159
- 0316729458153
- 0316729455152
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighLevothyroxine Sodium Tablets Recalled Nationwide for Subpotent Content
FDA (Drugs) · 2026-04-01
- HighLevothyroxine Tablets Recall for Wrong Strength Product Mix-Up
FDA (Drugs) · 2026-01-21
- HighLevothyroxine Sodium Tablets Recalled for Subpotency Issue Nationwide
FDA (Drugs) · 2025-10-15
- ModerateLevothyroxine Sodium Tablets Recalled Due to Subpotent Drug Content
FDA (Drugs) · 2025-07-23
- HighLevothyroxine Sodium Tablets Recalled Due to Below-Specification Potency
FDA (Drugs) · 2025-07-23
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27